Advanced search×

[Hereditary bone tumors].

Pathologe 31(6):471-6 (2010) PMID 20960198

Familial diseases leading to bone tumor formation are rare. They are mainly caused by genetic alterations of cell cycle constituent genes, such as retinoblastoma syndrome (RB1) and Li-Fraumeni syndrome (p53), of genes involved in growth-regulating transcriptional cascades, such as enchondromatosis (PTHR1) and multiple hereditary exostoses (EXT1, EXT2) or of genes maintaining chromosomal stability, such as Rothmund-Thomson (RECQL4), Werner (WRN) and Bloom syndromes (BLM). This leads to multiple benign bone tumors, which may undergo secondary malignant transformation (enchondromatosis: enchondromas, multiple hereditary exostoses: osteochondromas) or bone sarcomas, mainly osteosarcomas, such as primary (Li-Fraumeni, Rothmund-Thomson, Werner and Bloom syndromes) or secondary manifestations (retinoblastoma syndrome) of the underlying disease. Some of these lesions also carry an increased risk for developing additional malignant diseases. In contrast to sporadically occurring similar tumors, differences in manifestation in time, topography or histology may be present which can aid in the correct recognition of the underlying syndrome.

DOI: 10.1007/s00292-010-1364-4
Version: za2963e q8za0 q8zb3 q8zca q8zda q8zef q8zf8 q8zgc

Similar articles you may find interesting…

  1. Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.

    Cancer Discov (2013) PMID 23650262

    We show that, similar to Brca1 and Brca2, ablation of Palb2 in mouse mammary gland resulted in tumor development with long latency and the tumors harbored mutations in Trp53. Interestingly, impaired autophagy, due to monoallelic loss of the essential autophagy gene Becn1, reduced Palb2-associated ma...
  2. Children's Oncology Group's 2013 blueprint for research: Bone tumors

    Pediatr Blood Cancer 60(6):1009-1015 (2013) PMID 23255238

    In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves s...
  3. The Impact of Age and Clinical Factors in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette Guerin Therapy.

    Ultrastruct Pathol (2013) PMID 23634793

    The results of our study have shown that aging has no impact on the outcomes of high-risk NMIBC treated by BCG immunotherapy....